Suppr超能文献

别嘌醇的使用与白内障形成风险。

Allopurinol use and the risk of cataract formation.

作者信息

Clair W K, Chylack L T, Cook E F, Goldman L

机构信息

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

出版信息

Br J Ophthalmol. 1989 Mar;73(3):173-6. doi: 10.1136/bjo.73.3.173.

Abstract

Several reports have suggested an association between chronic allopurinol ingestion and cortical and subcapsular cataract formation. To examine this possibility we identified 51 allopurinol users and compared their lenses with those of 76 patients who did not use allopurinol. The existence of lens opacities and the level of visual acuity were assessed by review of medical records or by prospective ophthalmic examinations; in both phases of the study the examiners were blinded as to the patient's use or non-use of allopurinol. Three different outcomes were considered: formation of any cataract, formation of a posterior subcapsular cataract, and formation of a cataract contributing to a corrected visual acuity of 20/30 or worse. The risk ratio for the formation of any cataract was 1.3 (95% confidence interval: 0.8, 2.0), the risk ratio for the formation of a posterior subcapsular cataract was 0.9 (0.3, 2.0), and the risk ratio for the formation of a cataract contributing to a loss of visual acuity was 1.3 (0.6, 2.9). None of these risk ratios was changed appreciably after controlling for age, sex, hypertension, or diabetes. Thus, after a mean of 6.9 years of allopurinol use, we found no evidence to confirm that allopurinol users were at higher risk of acquiring cataracts.

摘要

几份报告表明,长期服用别嘌醇与皮质性和后囊下白内障的形成之间存在关联。为了检验这种可能性,我们确定了51名别嘌醇使用者,并将他们的晶状体与76名未使用别嘌醇的患者的晶状体进行了比较。通过查阅病历或进行前瞻性眼科检查来评估晶状体混浊的存在情况和视力水平;在研究的两个阶段,检查人员都不知道患者是否使用了别嘌醇。考虑了三种不同的结果:任何白内障的形成、后囊下白内障的形成以及导致矫正视力为20/30或更差的白内障的形成。任何白内障形成的风险比为1.3(95%置信区间:0.8,2.0),后囊下白内障形成的风险比为0.9(0.3,2.0),导致视力丧失的白内障形成的风险比为1.3(0.6,2.9)。在控制年龄、性别、高血压或糖尿病后,这些风险比均未发生明显变化。因此,在平均使用别嘌醇6.9年后,我们没有发现证据证实别嘌醇使用者患白内障的风险更高。

相似文献

1
Allopurinol use and the risk of cataract formation.别嘌醇的使用与白内障形成风险。
Br J Ophthalmol. 1989 Mar;73(3):173-6. doi: 10.1136/bjo.73.3.173.
2
Cataracts associated with allopurinol therapy.与别嘌醇治疗相关的白内障。
Am J Ophthalmol. 1982 Aug;94(2):137-40. doi: 10.1016/0002-9394(82)90067-8.
3
Allopurinol and cataracts.别嘌醇与白内障
Am J Ophthalmol. 1984 Sep 15;98(3):355-8. doi: 10.1016/0002-9394(84)90328-3.
6
Allopurinol therapy and cataractogenesis in humans.别嘌醇治疗与人类白内障形成
Am J Ophthalmol. 1982 Aug;94(2):141-6. doi: 10.1016/0002-9394(82)90068-x.
8
Medications and cataract. The Blue Mountains Eye Study.药物与白内障。蓝山眼研究。
Ophthalmology. 1998 Sep;105(9):1751-8. doi: 10.1016/S0161-6420(98)99049-2.

本文引用的文献

1
Allopurinol therapy and cataractogenesis in humans.别嘌醇治疗与人类白内障形成
Am J Ophthalmol. 1982 Aug;94(2):141-6. doi: 10.1016/0002-9394(82)90068-x.
2
Cataracts associated with allopurinol therapy.与别嘌醇治疗相关的白内障。
Am J Ophthalmol. 1982 Aug;94(2):137-40. doi: 10.1016/0002-9394(82)90067-8.
8
Allopurinol and cataracts.别嘌醇与白内障
Am J Ophthalmol. 1984 Sep 15;98(3):355-8. doi: 10.1016/0002-9394(84)90328-3.
10
Classification of human cataracts.人类白内障的分类
Arch Ophthalmol. 1978 May;96(5):888-92. doi: 10.1001/archopht.1978.03910050490021.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验